GPCR Latest Press Releases

-- December 17, 2025 --

Structure Therapeutics Announces Initiation of Phase 1 Clinical Study of Oral Small Molecule Amylin Receptor Agonist ACCG-2671 for the Treatment of Obesity Globe Newswire 8:30 AM

-- December 11, 2025 --

Structure Therapeutics Announces Closing of Upsized $747.5 Million Public Offering of ADSs and Pre-Funded Warrants and Full Exercise of the Underwriters' Option to Purchase Additional ADSs Globe Newswire 4:01 PM

-- December 9, 2025 --

Structure Therapeutics Announces Pricing of Upsized $650 Million Public Offering of ADSs and Pre-Funded Warrants Globe Newswire 11:15 PM

-- December 8, 2025 --

Structure Therapeutics Announces Proposed $500 Million Public Offering of American Depositary Shares and Pre-Funded Warrants Globe Newswire 4:01 PM

Structure Therapeutics Reports Positive Topline Data from ACCESS Program for its Once-Daily Oral Small Molecule GLP-1 Receptor Agonist, Aleniglipron Globe Newswire 8:00 AM

-- December 7, 2025 --

Structure Therapeutics to Report Data from ACCESS Clinical Program of Oral Small Molecule GLP-1 Receptor Agonist, Aleniglipron, on December 8, 2025 Globe Newswire 6:20 PM

-- November 6, 2025 --

Structure Therapeutics Reports Third Quarter 2025 Financial Results and Recent Highlights Globe Newswire 4:01 PM

Market Data Delayed 15 Minutes

Questions? Feedback?Olark live chat software